Overview
Third Harmonic Bio is a clinical-stage biopharmaceutical company that is advancing the next wave of medicine for allergy and inflammation.

Third Harmonic Bio is a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases through the development of a novel highly selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival.

Early clinical studies demonstrate that KIT inhibition has the potential to revolutionize the treatment of a broad range of mast-cell-mediated inflammatory diseases, and that a titratable, oral, intracellular small molecule inhibitor may provide the optimal therapeutic profile against this target.

Events
Investor contact

Contact Third Harmonic Bio investor relations at
investors@thirdharmonicbio.com